Cytovale

Cytovale is a medical diagnostics company developing innovative technologies for the rapid detection and assessment of immune-mediated diseases. By combining advanced biophysical analysis with routine blood samples, the company enables clinicians to identify high-risk patients earlier, supporting faster clinical decisions and improved patient outcomes in time-critical care settings.

Its FDA-cleared IntelliSep® test uses a standard blood draw to evaluate the biomechanical properties of white blood cells, providing clinicians with rapid insights into a patient's immune response in less than 10 minutes. Initially focused on sepsis, the platform helps emergency care teams quickly stratify patient risk, enabling earlier intervention for one of the world's most life-threatening medical conditions. Cytovale's technology is designed to complement existing clinical workflows by delivering actionable information during the critical window when treatment decisions have the greatest impact.

Driven by a mission to transform the diagnosis of rapidly progressing diseases, Cytovale continues to advance its proprietary cell analysis technology for broader clinical applications. Through innovative diagnostics that improve the speed and accuracy of immune system assessment, the company is helping healthcare providers deliver more timely, informed, and effective patient care.